Home » Newsletters » BioWorld Science

BioWorld Science

March 1, 2007

View Archived Issues

Recent RTI patent discloses novel therapeutic agents for irritable bowel syndrome

New agents for endocrine-related disorders imparted in recent patent literature

Recent patents disclose novel agents for obesity and disorders of lipid and bone metabolism

Studies reveal efficacy of fluticasone furoate nasal spray in allergic rhinitis

New trial evaluates topiramate and almotriptan for the treatment of medication overuse headache

Atorvastatin to be tested in new clinical trial for systemic lupus erythematosus

Vandetanib begins new phase III trial with pemetrexed for NSCLC

Javelin signs commercial supply agreement for Dyloject

Samaritan to market Elaprase in Greece and Cyprus

Second phase I trial of NGX-426 for chronic pain

DEBIO-9902 SR implant studied in phase II trial for Alzheimer's

BiPar Series B financing to support PARP inhibitor development

Roche and Kosan advance second-generation epothilone into phase II

Inex eyes close of Tekmira spin-out

Oral salmon calcitonin begins phase III study in osteoporosis

Vaccinex and Teva collaborate on VX-15

Paclitaxel poliglumex active, well tolerated in androgen-independent prostate cancer

MAP's Unit Dose Budesonide meets endpoints in phase II pediatric asthma trial

DMXAA increases efficacy of docetaxel in hormone-refractory prostate cancer

Par returns difimicin marketing rights to Optimer

Abiraterone active in androgen-independent, castration refractory prostate cancers

Maturation inhibitor PA-040 begins phase I study

CYT-500 enters clinic for hormone-refractory prostate cancer

Identification of ecallantide, an engineered, potent and selective inhibitor of plasma kallikrein

Humira approved for Crohn's disease

Cellular and molecular targets in tumor microenvironment considered for chemoprevention

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...